Literature DB >> 19590060

A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure.

Karl Lhotta1, Andreas R Janecke, Johanna Scheiring, Barbara Petzlberger, Thomas Giner, Verena Fally, Reinhard Würzner, Lothar B Zimmerhackl, Gert Mayer, Veronique Fremeaux-Bacchi.   

Abstract

BACKGROUND AND OBJECTIVES: Atypical hemolytic uremic syndrome (aHUS) is associated with mutations in genes encoding complement-regulatory proteins factor H, I and B and membrane cofactor protein. Recently, heterozygous gain-of-function mutations in the complement C3 gene have been found in patients with aHUS. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A large family with a C3 R570Q mutation is described. Clinical and laboratory findings of carriers of the mutation and unaffected family members are reported.
RESULTS: The index patient suffered from recurrent aHUS at age 22 and developed end-stage renal failure. Of 24 family members, nine harbored the C3 R570Q mutation. Carriers showed reduced or borderline C3 levels. Arterial hypertension was found in six family members, microhematuria in five and chronic kidney disease stage 3 in two elderly carrier patients. Despite marked consumption of C3, serum terminal complement complex levels were not elevated in carriers compared with other family members.
CONCLUSIONS: The penetrance of the C3 R570Q mutation to induce aHUS is incomplete and lower compared with mutations in other genes predisposing to the disease. The mutation is possibly also associated with hypertension, hematuria and chronic kidney disease, all of which may represent consequences of long-term complement activation in the renal vasculature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590060      PMCID: PMC2723975          DOI: 10.2215/CJN.06281208

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  32 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Terminal complement complexes in childhood type I membranoproliferative glomerulonephritis.

Authors:  Yasuaki Kobayashi; Osamu Hasegawa; Masataka Honda
Journal:  J Nephrol       Date:  2006 Nov-Dec       Impact factor: 3.902

Review 3.  Renal transplantation in HUS patients with disorders of complement regulation.

Authors:  Lothar Bernd Zimmerhackl; Johanna Scheiring; Friederike Prüfer; C Mark Taylor; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

Review 4.  Membrane cofactor protein and factor I: mutations and transplantation.

Authors:  David Kavanagh; Timothy H J Goodship
Journal:  Semin Thromb Hemost       Date:  2006-03       Impact factor: 4.180

5.  Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome.

Authors:  Friederike Prüfer; Johanna Scheiring; Sabine Sautter; Dorthe B Jensen; Ruth Treichl; Reinhard Würzner; L Bernd Zimmerhackl
Journal:  Semin Thromb Hemost       Date:  2006-03       Impact factor: 4.180

6.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.

Authors:  Elena Goicoechea de Jorge; Claire L Harris; Jorge Esparza-Gordillo; Luis Carreras; Elena Aller Arranz; Cynthia Abarrategui Garrido; Margarita López-Trascasa; Pilar Sánchez-Corral; B Paul Morgan; Santiago Rodríguez de Córdoba
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

7.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

Review 8.  Complement regulatory genes and hemolytic uremic syndromes.

Authors:  David Kavanagh; Anna Richards; John Atkinson
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

9.  Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.

Authors:  Peter F Zipfel; Matthew Edey; Stefan Heinen; Mihály Józsi; Heiko Richter; Joachim Misselwitz; Bernd Hoppe; Danny Routledge; Lisa Strain; Anne E Hughes; Judith A Goodship; Christoph Licht; Timothy H J Goodship; Christine Skerka
Journal:  PLoS Genet       Date:  2007-02-01       Impact factor: 5.917

10.  Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.

Authors:  Matthew C Pickering; Elena Goicoechea de Jorge; Rubén Martinez-Barricarte; Sergio Recalde; Alfredo Garcia-Layana; Kirsten L Rose; Jill Moss; Mark J Walport; H Terence Cook; Santiago Rodriguez de Córdoba; Marina Botto
Journal:  J Exp Med       Date:  2007-05-21       Impact factor: 14.307

View more
  24 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

Review 2.  Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind.

Authors:  Bertrand Boisson; Pierre Quartier; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2015-01-31       Impact factor: 7.486

3.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

4.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

Review 5.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

6.  Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Authors:  Elizabeth C Schramm; Lubka T Roumenina; Tania Rybkine; Sophie Chauvet; Paula Vieira-Martins; Christophe Hue; Tara Maga; Elisabetta Valoti; Valerie Wilson; Sakari Jokiranta; Richard J H Smith; Marina Noris; Tim Goodship; John P Atkinson; Veronique Fremeaux-Bacchi
Journal:  Blood       Date:  2015-01-21       Impact factor: 22.113

Review 7.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 8.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

Review 9.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 10.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.